标题
Therapeutic strategies to target RAS-mutant cancers
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 15, Issue 11, Pages 709-720
出版商
Springer Nature America, Inc
发表日期
2018-10-01
DOI
10.1038/s41571-018-0105-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling
- (2018) Michael C. Burns et al. ANALYTICAL BIOCHEMISTRY
- c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
- (2018) Manuel Sanclemente et al. CANCER CELL
- KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
- (2018) Chiara Ambrogio et al. CELL
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics
- (2018) Dominic Esposito et al. SEMINARS IN CANCER BIOLOGY
- Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
- (2018) Mehlika Hazar-Rethinam et al. Cancer Discovery
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Differential Effector Engagement by Oncogenic KRAS
- (2018) Tina L. Yuan et al. Cell Reports
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes
- (2017) Suparna Sarkar-Banerjee et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
- (2017) Marco Jost et al. MOLECULAR CELL
- Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
- (2017) M Pek et al. ONCOGENE
- Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
- (2017) Andrew M. Waters et al. Science Signaling
- Survival of pancreatic cancer cells lacking KRAS function
- (2017) Mandar Deepak Muzumdar et al. Nature Communications
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
- (2017) Timothy D. Martin et al. Cell Reports
- A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
- (2017) Grace R. Anderson et al. Cell Reports
- Kras and Tumor Immunity: Friend or Foe?
- (2017) Jane Cullis et al. Cold Spring Harbor Perspectives in Medicine
- Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
- (2017) Andrew M. Waters et al. Science Signaling
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- (2017) Mark Merchant et al. PLoS One
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
- (2016) Tikvah K. Hayes et al. CANCER CELL
- High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
- (2016) Thomas Horn et al. CANCER RESEARCH
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
- (2016) D. Oddo et al. CANCER RESEARCH
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Covalent targeting of acquired cysteines in cancer
- (2016) Marieke Visscher et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- RAS isoforms and mutations in cancer at a glance
- (2016) G. Aaron Hobbs et al. JOURNAL OF CELL SCIENCE
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit
- (2016) Daniel A. Ritt et al. MOLECULAR CELL
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Inhibition of RAS function through targeting an allosteric regulatory site
- (2016) Russell Spencer-Smith et al. Nature Chemical Biology
- Putting the brakes on KRAS-G12C nucleotide cycling
- (2016) Lydia Shipman NATURE REVIEWS DRUG DISCOVERY
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Protein prenylation: unique fats make their mark on biology
- (2016) Mei Wang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Drugging the Undruggable Ras — Immunotherapy to the Rescue?
- (2016) Carl H. June NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Identification of pyrazolopyridazinones as PDEδ inhibitors
- (2016) Björn Papke et al. Nature Communications
- Progress on Covalent Inhibition of KRASG12C
- (2016) K. D. Westover et al. Cancer Discovery
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
- (2016) Eliza Vakana et al. Oncotarget
- Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants
- (2016) Lisa Brenan et al. Cell Reports
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
- (2015) N. Jacque et al. BLOOD
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
- (2015) Ursula Germann et al. CANCER RESEARCH
- Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
- (2015) E. K. Ziemke et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Metabolic Dependencies in RAS-Driven Cancers
- (2015) A. C. Kimmelman CLINICAL CANCER RESEARCH
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
- (2015) Xiaolin Nan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
- (2015) J. Yun et al. SCIENCE
- Adoptive cellular therapy: A race to the finish line
- (2015) Carl H. June et al. Science Translational Medicine
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
- (2015) Q. J. Wang et al. Cancer Immunology Research
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
- (2014) Elda Grabocka et al. CANCER CELL
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
- (2014) A. N. Hata et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
- (2014) S. Okumura et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
- (2014) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
- (2014) Michael Lidsky et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
- (2014) Katja Schuster et al. MOLECULAR CANCER RESEARCH
- Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
- (2014) Asli Muvaffak et al. MOLECULAR CANCER RESEARCH
- Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
- (2014) M. I. Gross et al. MOLECULAR CANCER THERAPEUTICS
- Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
- (2014) M. R. Junttila et al. MOLECULAR CANCER THERAPEUTICS
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma
- (2014) Vito W. Rebecca et al. Pigment Cell & Melanoma Research
- H-Ras forms dimers on membrane surfaces via a protein-protein interface
- (2014) W.-C. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
- (2014) J. C. Hunter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
- (2014) Michael C. Burns et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance
- (2014) C. A. Martz et al. Science Signaling
- Dimerization Opens New Avenues into Ras Signaling Research
- (2014) E. Santos Science Signaling
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
- (2014) Z. Zhu et al. Cancer Discovery
- Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
- (2014) C. E. Burd et al. Cancer Discovery
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Ral GTPases in tumorigenesis: Emerging from the shadows
- (2013) David F. Kashatus EXPERIMENTAL CELL RESEARCH
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
- (2013) Cosimo Commisso et al. NATURE
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
- (2013) Jaekyoung Son et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model
- (2012) H. Y. Chow et al. CANCER RESEARCH
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- KRASG12D- and BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling
- (2012) V. A. Appleman et al. MOLECULAR CANCER RESEARCH
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
- (2012) T. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
- (2012) Amy Young et al. Cancer Discovery
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
- (2011) C. Babij et al. CANCER RESEARCH
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
- (2011) D. Gaglio et al. Molecular Systems Biology
- Regulating the regulator: post-translational modification of RAS
- (2011) Ian M. Ahearn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- (2011) P. I. Poulikakos et al. Science Signaling
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
- (2010) M. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started